Long COVID Has Measurable Biological Drivers. This Protocol Addresses All of Them.

What Is Long COVID?

Long COVID, formally called PASC (Post-Acute Sequelae of SARS-CoV-2), affects an estimated 10 to 30% of those infected and is recognized by the WHO, CDC, and NIH as a distinct medical condition. It has measurable biological markers: elevated inflammatory cytokines, persistent microclots visible on electron microscopy, small fiber neuropathy on skin biopsy, measurable autonomic dysfunction, and reduced immune T-cell counts. Standard clinical testing does not capture these specific mechanisms, which is why patients are often told their results are normal when the relevant tests simply have not been ordered.

The biology involves at least five overlapping mechanisms. Spike protein fragments and viral RNA can persist in gut tissue, lymph nodes, and monocytes months after acute infection resolves, maintaining chronic immune activation with elevated TNF-a, IL-6, and interferon signaling. Amyloid-fibrin microclots formed during acute infection persist in small blood vessels, resistant to normal fibrinolysis, impairing oxygen and nutrient delivery at the capillary level and contributing to the characteristic fatigue, brain fog, and exercise intolerance. Autonomic nervous system dysregulation produces POTS-like symptoms in many patients, including orthostatic tachycardia and brain fog on standing. Mitochondrial dysfunction from viral oxidative damage produces the disproportionate fatigue and post-exertional malaise. And in a significant subset, long COVID triggers mast cell activation, adding histamine-driven multi-system symptoms to the picture.

Who the Long COVID Protocol Is For

This protocol is built for patients who are dealing with one or more of the following:

• Fatigue, brain fog, shortness of breath, or other symptoms persisting more than 12 weeks after a COVID infection
• Post-exertional malaise where symptoms worsen significantly 12 to 48 hours after physical or cognitive activity
• Heart rate instability on standing, orthostatic symptoms, or autonomic complaints that began post-COVID
• Standard lab work that comes back normal while the experience of ongoing illness remains real and limiting

How the Long COVID Protocol Works

The baseline panel for this protocol includes inflammatory cytokines, Vitamin D, coagulation markers, NAD+ status, autonomic markers, and where indicated, microclot assessment and mast cell mediators. The protocol moves through three stages targeting each overlapping mechanism simultaneously.

What the Protocol May Include: NAC and liposomal glutathione for viral oxidative stress and mitochondrial protection; nattokinase at therapeutic dose for fibrinolytic microclot reduction, with published evidence specific to long COVID; quercetin for mast cell stabilization and Nrf2 antioxidant activation; high-dose omega-3 fatty acids for microclot-promoting cytokine reduction and immune resolution; and Vitamin D repletion, which is nearly universal in long COVID patients and directly regulates the antiviral immune response through Type I interferon pathways. As the protocol advances, injectable vitamins at the clinic deliver Vitamin C (with published post-viral recovery evidence), glutathione, arginine for nitric oxide and microvascular circulation improvement, and injectable zinc for antiviral immune function support. Stage 3 adds peptides including BPC-157 for gut barrier repair and gut-based viral reservoir reduction, KPV and PE-22-28 for neuroinflammation, MOTS-c for mitochondrial energy restoration, TB4 for tissue repair and microvascular recovery, and Thymosin Alpha-1 for patients with significant immune dysregulation requiring direct Th1/Th2 rebalancing.

Stage 1 (Pathway) prioritizes the most immediately impactful interventions: oxidative stress reduction, microclot treatment, and mast cell stabilization. Stage 2 (Roadmap) adds injectable delivery at the clinic for therapeutic-level antiviral and recovery support. Stage 3 (Atlas) is the complete protocol for complex long COVID presentations with significant autonomic, neurological, or immune involvement.